IL216624A - Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene - Google Patents

Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene

Info

Publication number
IL216624A
IL216624A IL216624A IL21662411A IL216624A IL 216624 A IL216624 A IL 216624A IL 216624 A IL216624 A IL 216624A IL 21662411 A IL21662411 A IL 21662411A IL 216624 A IL216624 A IL 216624A
Authority
IL
Israel
Prior art keywords
deoxymannose
epimerase
keto
reductase
glycoprotein
Prior art date
Application number
IL216624A
Other languages
English (en)
Hebrew (he)
Other versions
IL216624A0 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL216624A0 publication Critical patent/IL216624A0/en
Publication of IL216624A publication Critical patent/IL216624A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271GDP-L-fucose synthase (1.1.1.271)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL216624A 2009-06-02 2011-11-27 Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene IL216624A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US34885810P 2010-05-27 2010-05-27
PCT/US2010/036914 WO2010141478A1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells

Publications (2)

Publication Number Publication Date
IL216624A0 IL216624A0 (en) 2012-02-29
IL216624A true IL216624A (en) 2015-02-26

Family

ID=42338231

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216624A IL216624A (en) 2009-06-02 2011-11-27 Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene

Country Status (16)

Country Link
US (8) US8409838B2 (OSRAM)
EP (3) EP3279326B1 (OSRAM)
JP (4) JP5744856B2 (OSRAM)
KR (2) KR101641526B1 (OSRAM)
CN (1) CN102459603B (OSRAM)
AU (1) AU2010256753B2 (OSRAM)
BR (1) BRPI1010035A2 (OSRAM)
CA (1) CA2764370C (OSRAM)
DK (3) DK2808393T3 (OSRAM)
ES (2) ES2661074T3 (OSRAM)
HU (1) HUE038596T2 (OSRAM)
IL (1) IL216624A (OSRAM)
PL (3) PL2808393T3 (OSRAM)
SG (1) SG176251A1 (OSRAM)
TW (1) TWI513818B (OSRAM)
WO (1) WO2010141478A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
ES2661074T3 (es) 2009-06-02 2018-03-27 Regeneron Pharmaceuticals, Inc. Células deficientes de fucosilación
BR112013022832A2 (pt) 2011-03-06 2016-11-22 Merck Serono Sa linhagens de células de baixo teor de fucose e usos das mesmas
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
CN106459199B (zh) 2014-03-11 2021-01-01 瑞泽恩制药公司 抗-egfrviii抗体及其用途
KR20250012733A (ko) * 2014-05-30 2025-01-24 뉴 잉글랜드 바이오랩스, 인크 탈당화 시약 및 방법
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP6983772B2 (ja) * 2015-11-02 2021-12-17 ジェネンテック, インコーポレイテッド タンパク質のフコシル化及び脱フコシル化形態の作製方法
JP6674028B2 (ja) 2016-01-06 2020-04-01 アウトルック セラピューティクス,インコーポレイティド モノクローナル抗体組成物中のアフコシル化種の調節
CA3013336A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CA3015371A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
BR112018071283A2 (pt) * 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
US20210317499A1 (en) * 2018-08-29 2021-10-14 United Biopharma Inc. Afucosylated antibodies and manufacture thereof
TWI861023B (zh) 2018-10-29 2024-11-11 日商免疫生物研究所股份有限公司 抗hiv抗體及其製造方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
EP4157868A1 (en) 2020-05-26 2023-04-05 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
US11999777B2 (en) 2020-06-03 2024-06-04 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4359440A1 (en) 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
MX2024000563A (es) 2021-07-14 2024-04-10 Regeneron Pharma Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2.
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN119095875A (zh) 2022-03-02 2024-12-06 瑞泽恩制药公司 高滴度抗体的制造工艺

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
AU2002245272B2 (en) 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
RU2479629C2 (ru) 2007-03-07 2013-04-20 Гликофи, Инк. Продукция гликопротеинов с модифицированным фукозилированием
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2010018847A1 (ja) 2008-08-13 2010-02-18 協和発酵キリン株式会社 遺伝子組換えプロテインs組成物
ES2661074T3 (es) * 2009-06-02 2018-03-27 Regeneron Pharmaceuticals, Inc. Células deficientes de fucosilación
BR112013022832A2 (pt) 2011-03-06 2016-11-22 Merck Serono Sa linhagens de células de baixo teor de fucose e usos das mesmas

Also Published As

Publication number Publication date
US20170211115A1 (en) 2017-07-27
AU2010256753A1 (en) 2012-01-12
CA2764370C (en) 2018-08-21
SG176251A1 (en) 2011-12-29
ES2661074T3 (es) 2018-03-27
KR20120029443A (ko) 2012-03-26
US20130164786A1 (en) 2013-06-27
EP2438171B1 (en) 2014-12-17
HK1163745A1 (en) 2012-09-14
US12054751B2 (en) 2024-08-06
TW201107469A (en) 2011-03-01
IL216624A0 (en) 2012-02-29
US20210254022A1 (en) 2021-08-19
JP6211642B2 (ja) 2017-10-11
AU2010256753B2 (en) 2013-11-28
BRPI1010035A2 (pt) 2015-08-25
US9550823B2 (en) 2017-01-24
JP2012528594A (ja) 2012-11-15
ES2527173T3 (es) 2015-01-21
KR101441437B1 (ko) 2014-09-25
CN102459603A (zh) 2012-05-16
US20230295583A1 (en) 2023-09-21
PL2808393T3 (pl) 2018-04-30
JP2015051021A (ja) 2015-03-19
EP2438171A1 (en) 2012-04-11
EP2808393A3 (en) 2015-03-11
DK3279326T3 (da) 2020-12-21
US20160090410A1 (en) 2016-03-31
US11560550B2 (en) 2023-01-24
EP3279326B1 (en) 2020-10-14
EP3279326A1 (en) 2018-02-07
US20190024129A1 (en) 2019-01-24
KR101641526B1 (ko) 2016-07-21
KR20140039340A (ko) 2014-04-01
EP2808393B1 (en) 2018-01-10
PL3279326T3 (pl) 2021-03-08
CA2764370A1 (en) 2010-12-09
US9206455B2 (en) 2015-12-08
DK2438171T3 (en) 2015-01-26
US20200080124A1 (en) 2020-03-12
JP2017006147A (ja) 2017-01-12
US10006070B2 (en) 2018-06-26
PL2438171T3 (pl) 2015-04-30
TWI513818B (zh) 2015-12-21
JP2016104045A (ja) 2016-06-09
JP5744856B2 (ja) 2015-07-08
HK1249547A1 (en) 2018-11-02
US8409838B2 (en) 2013-04-02
CN102459603B (zh) 2013-11-06
HK1198180A1 (en) 2015-03-13
US20100304436A1 (en) 2010-12-02
DK2808393T3 (en) 2018-03-12
WO2010141478A1 (en) 2010-12-09
HUE038596T2 (hu) 2018-10-29
EP2808393A2 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
IL216624A (en) Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene
EP2461418B8 (en) Battery module, and method for cooling a battery module
IL252045B (en) Isolated nucleic acid, expression vector and cell culture comprising the nucleic acid
BR112012001351A2 (pt) Método, célula de levedura engenheirada geneticamente, e, co-cultura de bactéria-levedura.
IL216902A0 (en) Methods for culturing stem and progentitor cells
IL217026A0 (en) Capsule, system and method for the prepartion of a beverage and a method for manufacturing such a capsule
EP2477262A4 (en) Gas diffusion layer and process for production thereof, and fuel cell
EP2506505A4 (en) Load distribution system, load distribution method, and program
TWI563674B (en) Method for making a solar battery,and solar battery
PL2371924T3 (pl) Sposoby zwiększania produkcji gazu i odzyskiwania ładunku
EP2660345A4 (en) Steel sheet having enhanced ductility for a molding member, molding member, and method for manufacturing same
EP2415693A4 (en) Composite tank, manufacturing method therefor, and wing
EP2408021A4 (en) Process for producing solar battery, and solar battery
GB0904877D0 (en) Interface module, system and method
GB0909110D0 (en) Biometric method, system and computer program
IL219600A0 (en) Germline stem cell banking system
PL2414300T3 (pl) Sposób wytwarzania szklanego pojemnika i odpowiedni pojemnik
EP2473583A4 (en) SYSTEM AND METHOD FOR PRODUCING BIODIESEL
SG11201402586YA (en) Mutant xylanase, manufacturing method and use therefor, and method for manufacturing saccharified lignocellulose
EP2677593A4 (en) CELL HOUSING AND STRUCTURE FOR FIXING THE CELL HOUSING
ZA201107892B (en) High-volume-manufacture fuel cell arrangement and method for production thereof
EP2579373A4 (en) OPERATING METHOD FOR FUEL CELL AND FUEL CELL SYSTEM
IL218026A0 (en) Processes for culturing prokaryotic cells, cells produced thereby and uses thereof
EP2555251A4 (en) Method for manufacturing solar cell, and solar cell
EP2428562A4 (en) METHOD OF STEM CELL CULTIVATION

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed